OTC Markets
Prev Close 0.15
Day Low/High 0.12 / 0.16
52 Wk Low/High 0.03 / 0.27
Exchange OTC Markets
Shares Outstanding 90.69B
Market Cap 14.06M
Div & Yield N.A. (N.A)

Cardax Q1 2017 Revenues Triple Vs. Prior Two Quarters Combined

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced first quarter 2017 revenues from ZanthoSyn, the Company's premium astaxanthin over-the-counter dietary supplement, were more than three times 2016 revenues, which began in...

Cardax Astaxanthin Compound CDX-085 Stimulates Anti-Aging Gene In Mice

Cardax, Inc. ("Cardax") (OTCQB:CDXI) and the University of Hawaii ("UH") announced today that Cardax's proprietary astaxanthin compound, CDX-085, demonstrated an almost 90% increase in FOXO3 gene expression in mice (p=0.

Cardax Secures Access To Funds Under Equity Purchase Agreement

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that the registration statement necessary to access funds under the previously reported Equity Purchase Agreement ("EPA") has been declared effective by the Securities...

Cardax Takes Important Step To Access Funds Under Equity Purchase Agreement

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced that it is incorporating its 3 rd quarter financial results as an amendment into the S-1 registration statement previously filed with the SEC.

Cardax Announces Launch Of ZanthoSyn™ In Hawaii GNC Stores

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that ZanthoSyn, Cardax's safe anti-inflammatory supplement for general health,* is being rolled out to all 29 GNC stores in Hawaii, where Cardax is headquartered.

Cardax Appoints Global Healthcare Executive As Independent Director

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today the appointment of Michele Galen, an attorney and former Chief Communications Officer for both Novartis AG and Shire plc, as an independent member of its Board of...

Cardax Reports Successful Launch Of ZanthoSyn™

Cardax, Inc. ("Cardax") (OTCQB:CDXI) is pleased to announce the successful launch of ZanthoSyn, our first product to help consumers safely address their inflammatory health.

Cardax Launches First Product ZanthoSyn™

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it has launched its first commercial product, ZanthoSyn ™, a safe anti-inflammatory for general health.

Cardax Enters Into Equity Purchase Agreement For Financing Of Up To $5 Million

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it has entered into an Equity Purchase Agreement ("EPA") with an affiliate of Southridge LLC ("Southridge"), an institutional investor.

Cardax Awarded U.S. Inflammation Patent

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it was awarded a U.

Cardax Product Candidates Demonstrate Superior Bioavailability Vs. Microalgal Astaxanthin In Monkey Study

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that its astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated more than two and one-half times higher oral bioavailability than a leading microalgal...

Cardax Raises Additional $500,000 In Financing

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it has closed on an additional $500,000 in equity financing, bringing the year-to-date amount raised in its issuer-directed unit offering to $1,125,000.

Cardax Initiates Monkey Study To Compare Bioavailability Of Patented Consumer Health Product Candidate CDX-085 To Microalgal Astaxanthin

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today that it initiated a single-dose pharmacokinetic study in non-human primates (monkeys) to compare the bioavailability (exposure) of CDX-085, the Company's patented...

Capsugel: Http://

Capsugel and Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today a collaboration to develop unique astaxanthin products for the consumer health market.